Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 541-547

  Vinks, Alexander A ^a   Den Hollander, Jan G ^b   Overbeek, Shelley E ^b   Jelliffe, Roger W ^c   Mouton, Johan W ^b,d  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CALCULATION; CLINICAL TRIAL; COMPARTMENT MODEL; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MICHAELIS MENTEN KINETICS; NONLINEAR SYSTEM; PRIORITY JOURNAL;

ADULT; AREA UNDER CURVE; BAYES THEOREM; CYSTIC FIBROSIS; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; NONLINEAR DYNAMICS; PENICILLINS; PIPERACILLIN;

EID: 0037311491     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.541-547.2003     Document Type: Article

References (28)

1. Auclair, B., and M. P. Ducharme. 1999. Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses. Antimicrob Agents Chemother. 43:1465-1468.
2. Batra, V. K., J. A. Morrison, K. C. Lasseter, and V. A. Joy. 1979. Piperacillin kinetics. Clin. Pharmacol. Ther. 26:41-53.
3. Bergan, T., and J. D. Williams. 1982. Dose dependence of piperacillin pharmacokinetics. Chemotherapy 28:153-159.
4. Bryson, H. M., and R. N. Brogden. 1994. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 47:506-535.
5. Craig, W. A., and S. C. Ebert. 1992. Continuous infusion of beta-lactam antibiotics. Antimicrob. Agents Chemother. 36:2577-2583.
6. DuBois, D., and E. F. DuBois. 1916. A formula to estimate the appropriate surface area if height and weight are known. Arch. Intern. Med. 17:1065-1072.
7. Hallynck, T. H., H. H. Soep, J. A. Thomis, J. Boelaert, R. Daneels, and L. Dettli. 1981. Should clearance be normalised to body surface or to lean body mass? Br. J. Clin. Pharmacol. 11:523-526.
8. Jelliffe, R. W., and S. M. Jelliffe. 1971. Estimation of creatinine clearance from changing serum-creatinine levels. Lancet 2:710.
9. Jelliffe, R. W., A. Schumitzky, M. Van Guilder, M. Liu, L. Hu, P. Maire, P. Gomis, X. Barbaut, and B. Tahani. 1993. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther. Drug Monit. 15:380-393.
10. Kucharczyk, N. 1993. Estimation of the lower limit of quantitation, a method detection performance parameter for biomedical assays, from calibration curves. J. Chromatogr. 612:71-76.
11. Ludden, T. M. 1991. Nonlinear pharmacokinetics: clinical implications. Clin. Pharmacokinet. 20:429-446.
12. McCarty, J. M., S. J. Tilden, P. Black, J. C. Craft, J. Blumer, W. Waring, and N. A. Halsey. 1988. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatr. Pulmonol. 4:201-204.
13. Proost, J. H., and D. K. Meijer. 1992. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput. Biol. Med. 22:155-163.
14. Reed, M. D., J. Goldfarb, T. S. Yamashita, E. Lemon, and J. L Blumer. 1994. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob. Agents Chemother. 38:2817-2826.
15. Reed, M. D., R. C. Stern, C. M. Myers, J. D. Klinger, T. S. Yamashita, and J. L. Blumer. 1987. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr. Pulmonol. 3:101-109.
16. Schumitzky, A. 1991. Nonparametric EM algorithms for estimating prior distributions. Appl. Math. Comput. 45: 141-157.
17. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
18. Sorgel, F., and M. Kinzig. 1993. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J. Antimicrob. Chemother. 31(Suppl. A):39-60.
19. Tjandramaga, T. B., A. Mullie, R. Verbesselt, P. J. De Schepper, and L. Verbist. 1978. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob. Agents Chemother. 14:829-837.
20. Touw, D. J. 1998. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm. World Sci. 20:149-160.
21. Touw, D. J., A. A. Vinks, F. Jacobs, H. G. Heijerman, and W. Bakker. 1996. Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis. Ther. Drug Monit. 18:562-569.
22. Van der Vaart, F. J. 1992. Guidelines for validation of analytical procedures in pharmaceutical and biopharmaceutical analyis. Pharm. Weekbl. 46:1229-1235.
23. Vinks, A. A., R. W. Brimicombe, H. G. Heijerman, and W. Bakker. 1997. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J. Antimicrob. Chemother. 40:125-133.
24. Vinks, A. A., J. W. Mouton, H. G. M. Heijerman, and W. Bakker. 1999. Pharmacodynamic and pharmacokinetic optimisation of treatment with β-lactam antibiotics in cystic fibrosis. Rev. Med. Microbiol. 10:89-107.
25. Wang, J. P., J. D. Unadkat, S. M. al-Habet, T. A. O'Sullivan, J. Williams-Warren, A. L. Smith, and B. Ramsey. 1993. Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin. Clin. Pharmacol. Ther. 54:293-302.
26. Woodland, C., D. Blowey, S. Ito, M. Spino, and G. Koren. 1998. Hypothetical framework for enhanced renal tubular secretion of drugs in cystic fibrosis. Med. Hypotheses 51:489-491.
27. Wysocki, M., F. Delatour, F. Faurisson, A. Rauss, Y. Pean, B. Misset, F. Thomas, J. F. Timsit, T. Similowski, H. Mentec, L. Mier, and D. Dreyfuss. 2001. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45:2460-2467.
28. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.